Riccardo Panella
Founder & Chief Scientific Officer Resalis Therapeutics
Dr. Riccardo Panella is a visionary scientist-entrepreneur advancing RNA-based therapeutics at the intersection of academia and industry. As Founder and CSO of Resalis Therapeutics, he leads the development of innovative RNA-targeted treatments, while also serving as Associate Professor at the Center for RNA Medicine and Coordinator of Research at the European Biomedical Research Institute of Salerno, where he bridges cutting-edge research with clinical translation.
With a unique dual training in science and business, Dr. Panella holds a mini-MBA from Harvard Business School and a PhD in Oncology and Cancer Biology from the University of Perugia. His academic journey includes impactful postdoctoral research at Harvard Medical School and Beth Israel Deaconess Medical Center, followed by a faculty position as Research Assistant Professor at the Desert Research Institute. His work exemplifies how deep scientific expertise, combined with business acumen, can accelerate breakthroughs from bench to bedside.
Seminars
- RES-101, a first-in-class miR-22 inhibitor, restores lipid biosynthesis and drives adipose browning for sustained reduction of unhealthy fat and improved body composition
- Disease-modifying approach that can be synergistically combined with other therapeutic modalities
- Selectively addressing excess of adiposity to promote high quality body weight loss
- Targeting inflammation to restore metabolic homeostasis and leverage dual action therapies for metabolic restoration and reduction in chronic inflammation
- Promoting adipose browning and lean mass retention through RNA-Based miR-22 inhibition for fat remodelling and improved body composition
